The U.S. stock market has managed to overcome challenge after challenge in 2025. Despite tariffs and a slew of economic and geopolitical pressures, the major U.S. stock indexes are basically at all-time highs. That just hasn’t been the case for biotech and emerging pharma stocks.
Oggonomics has tracked multiple Wall Street analyst reports calling for massive upside in some small-cap players in the last week. Some of these analyst reports were even forecasting 100% to 400% in potential upside if their expectations pan out.
Here is where biotechs have come up short against the broader market indexes in 2025. The NASDAQ-100 was up over 12% YTD and the S&P 500 was up over 10% YTD. Meanwhile, the volatile biotech sector has been lagging as a whole. The SPDR Biotech ETF (XBI) was last seen up less than 1% YTD, and the VanEck Biotech ETF (BBH) was up less than 5% YTD.
The good news is that most biotech stocks probably don’t have to care about tariffs (too much, at least) and geopolitics (to an extent). What the biotech sector does have to contend with is a risk-on or risk-off mentality by investors. And there are absolutely some serious risks pertaining to how much insurance companies and how much governments are willing to pay for their breakthrough drugs and treatments.
The week of April 29, 2025 has seen some incredible upside forecasts from biotech analysts. Seeing implied upside of 100% to 400% just is not the norm. Analyst “Buy” and “Outperform” ratings in Blue Chips and established companies generally target implied upside of 8% to 12% on average. And most of those Blue Chip stocks pay dividends, while emerging biotechs do not.
There always seems to be opportunities in cancer, diabetes, inflammation and other conditions which offer blockbuster drug potential. If biotech studies fail to reach their goals, or if competing studies suddenly look more promising, all those biotech ambitions can go out the door with hundreds of millions of dollars down the drain. Some biotechs can implode down to zero — and others can become biotech zombies that stay public but have little to nothing to attract any investors.
Oggonomics always reminds readers that no single analyst report should ever be the sole reason to buy or sell a stock. Analysts can get their outlook wrong. Fundamentals can change on a moment’s notice. And unexpected and unforeseen issues can sabotage all great calls for upside. Those risks are particularly true for unproven biotech and biohealth stocks that have generated little or no real revenue after years of pre-clinical studies.
Don’t forget that there are zero assurances or guarantees in any of those analyst reports that were sent to clients. And it is very possible that some (or all) of these emerging companies may fall well short of the great expectations outlined by each analyst. NASDAQ short interest data as of August 15 has also been included to show what sort of conviction that “strategic sellers” may have over those bullish buyers.
BIMOEA FUSION
Biomea Fusion, Inc. (NASDAQ: BMEA) may not be a household name, but one firm believes the Biomea was started with a Buy rating and a $5.00 price target at Jefferies. That’s an implied upside roughly 200% from its prior $1.86 pre-call close if Jefferies is accurate in its assessments.
Biomea is a clinical-stage biotech (i.e. non-revenue stage) that is focused on developing oral small molecule treatments for diabetes and obesity medicines. Jefferies referred to it as having mechanism of action that could fundamentally address a root cause of diabetes. Its lead asset icovamenib is being studied in both type-2 diabetes and type-1 diabetes, and it is expected to release an update on Phase 2 data in the coming months.
Biomea’s 52-week trading range is $1.29 to $13.07 and its market cap was just $111 million ahead of the analyst call. The NASDAQ short interest as of August 15 was 8.34 million shares (11.1 days to cover).
HUMACYTE
Humacyte, Inc. (NASDAQ: HUMA) is only in the early stages of launching Symvess in vascular trauma, but Barclays started coverage with an Overweight rating and set a $3.50 price target (versus $1.47 close ahead of the call) for an implied upside of more than 100%.
The launch is said to be the first of four initial indications for its engineered vessel with an initial indication that addresses significant challenges and costs associated with vascular trauma patients. Despite a $240 million market cap, Barclays is projecting potential sales north of $600 million.
Humacyte was trading at $1.55 after the call and its 52-week range is $1.15 to $6.77. The NASDAQ short interest as of August 15 for Humacyte was 34.25 million shares (4.6 days to cover).
INVENTIVA
Inventiva S.A. (NASDAQ: IVA) was started as Overweight with a $26 price target at Piper Sandler. This implies more than 400% upside if the analyst report is proven true. Its stock rallied handily from the prior $4.59 closing price. Please understand that the daily trading volume was extremely thin ahead of this call.
Inventiva’s lead asset is lanifibranor that targets metabolic dysfunction-associated steatohepatitis. The firm expects a Phase 3 study readout in a year or so, and the firm sees a buying opportunity at the current share price as its oral asset is “de-risked” for probability of success.
With a $5.75 share price late in the week, its 52-week range was $1.53 to $5.80. Inventiva’s market cap was nearly $800 million after the jump in its stock. The NASDAQ short interest as of August 15 was only 28,000 shares (about 1 day to cover).
NEW AMSTERDAM
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) was initiated with an Overweight rating and $45 price target at Wells Fargo. With a $24.70 price at the time, this represented 80% in implied upside rather than over 100% upside. Another target had been as high as $52 at a competing firm earlier in 2025.
Wells Fargo believes that NewAmsterdam’s cholesteryl ester transfer protein inhibition offers a “new frontier” for lipid lowering. The firm sees a multi-billion-dollar opportunity if it pans out, with obicetrapib built on the foundations of prior CETP inhibitors. It sees the PREVAIL study set up for success.
Back in May, Phase 3 data showed that obicetrapib as an adjunct to statins reduced LDL-C by 50% and 35%, respectively. Phase 2 data of obicetrapib in combination with moderate-dose statins showed LDL-C reductions of approximately 70%.
NewAmsterdam’s 52-week trading range is $14.06 to $27.29 and its market cap is $2.7 billion. The NASDAQ short interest as of August 15 was 7.33 million shares (8.7 days to cover).
OCULIS
Oculis Holding AG (NASDAQ: OCS) is a small-cap targeting the larger issues of diabetic macular edema. Needham & Co. started coverage of Oculis with a Buy rating and issued a $36 price target, implying more than 100% upside from the $17.33 share price. This stock also had incredibly thin trading volume prior to this latest analyst report.
Oculis’ lead-asset OCS-01 is hoping to offer the first non-invasive therapy for diabetic macular edema. Its OCS-02 is also show to offer a biologic mechanism of action to treat dry-eye disease using eye drops. Needham called it an “under-the-radar” stock story with data coming after the start of 2026.
Its 52-week range is $11.56 to $23.08 and its market cap is about $900 million. The NASDAQ short interest as of August 15 was 40,450 shares (6.8 days to cover).
SENSEONICS
Senseonics Holdings, Inc. (NYSEArca: SENS) is a rare call from Barclays because the stock is under $1.00. Barclays assigned an Overweight rating and a $1.50 price target, versus a price of only about $0.50 at the time.
The company’s Eversense 365 implantable continuous glucose monitoring sensor system is shown to create a new category for diabetes patients who suffer from fatigue. Barclays projected that this 365 system can drive significant demand into 2026 and beyond.
Senseonics was last seen closer to $0.46 late in the week, with a 52-week range of $0.25 to $1.40. Its market cap is $375 million. The NASDAQ short interest as of August 15 was not available due its listing status.
VIR BIOTECHNOLOGY
Vir Biotechnology, Inc. (NASDAQ: VIR) could face nearly 200% in implied upside if BofA’s views come to fruition. BofA raised Vir Biotechnology’s rating to Buy from Neutral and raised its price objective to $14 from $12 in that call.
BofA’s upside view is that the market is currently underestimating the potential for its treatment of severe liver disease caused by hepatitis. The firm also noted a minimal value attributed to Vir’s T-cell engager oncology programs even though the initial proof-of-concept data has potential.
Vir Biotechnology closed at $4.44 prior to the analyst call, but it closed at $5.23 the day after the call. Its 52-week trading range is $4.16 to $14.45 and its market cap is $750 million. The NASDAQ short interest as of August 15 for Vir Biotechnology was almost 11.5 million shares (9.8 days to cover).
DISCLAIMERS
The analyst ratings and price targets mentioned above have been credited to each firm by name. Investors should keep in mind that analysts sometimes get their thesis and outlook wrong, which can result in potentially large losses for investors. Another risk is that market/company fundamentals can change from positive to negative in an instant.
Oggonomics does not have any formal ratings and does not maintain any price targets of its own on the companies mentioned above in this reporting. Interpretations of how positive or negative the analyst calls are can also wildly vary from investor to investor. Some investors will even use every bit of good news to sells shares (or short sell).
No analyst ratings and their price targets, even those with the strongest conviction or strongest pessimism, ever come with any guarantees of profits. Analyst reports also never have money-back guarantees in the event that investors lose money.
